Contractile stimuli can sensitize myosin to Ca 2ϩ by activating RhoA kinase (ROK) and PKC that inhibit myosin light chain phosphatase (MLCP) activity. Relaxant stimuli, acting through PKA and PKG (cyclic nucleotide-dependent protein kinases), and pretreatment with contractile agents such as phenylephrine (PE), can desensitize myosin to Ca 2ϩ . It is unknown precisely how these stimuli cause Ca 2ϩ desensitization. To test the hypothesis that PKA, PKG, and PE pretreatment signaling systems converge to cause relaxation by inhibition of ROK in intact, isolated tissues, we examined the effects of forskolin (FSK; PKA activation), 8-bromo-cGMP (8br-cGMP; PKG activation), and PE pretreatment on KCl-induced force maintenance in rabbit arteries, a response nearly completely dependent on ROK activation. PE pretreatment and agents activating PKA and PKG caused Ca 2ϩ desensitization by inhibiting KCl-induced tonic force and MLC phosphorylation without inhibiting intracellular [Ca 2ϩ ]. At pCa 5 in ␤-escin-permeabilized muscle, FSK and 8b-cGMP accelerated the relaxation rate when tissues were returned to pCa 9, suggesting that both agents can elevate MLCP activity. However, a component of the Ca 2ϩ desensitization attributed to PKG activation in intact tissues appeared to involve a MLC phosphorylation-independent component. Inhibition of KCl-induced tonic force by the ROK inhibitor, Y-27632, and by PE pretreatment, were synergistically potentiated by 8b-cGMP, but not FSK. FSK and PE pretreatment, but not 8b-cGMP, inhibited the KCl-induced increase in site-specific myosin phosphatase target protein-1 phosphorylation at Thr 853 . These data support the hypothesis that PKA and PE pretreatment converge on a common Ca 2ϩ -desensitization pathway, but that PKG can act by a mechanism different from that activated by PKA and PE pretreatment. Contractile stimuli may also activate signaling systems leading to inhibition of MLC phosphatase (MLCP), and both systems will elevate MLC phosphorylation, which acts as a "switch" permitting actomyosin cross-bridge cycling, muscle shortening, and force development (see Refs. 30 and 45 for reviews). Because contractile signaling systems that cause inhibition of MLCP can elevate contractile force independently of further increases in [Ca 2ϩ ] i , this mechanism is termed "Ca 2ϩ sensitization" (see Refs. 10 and 45 for reviews). Relaxant stimuli activate cAMP-and cGMP-dependent protein kinases (PKA and PKG, respectively) that reduce the degree of MLC phosphorylation by reducing [Ca 2ϩ ] i (and thus MLCK activity) and by increasing MLCP activity to cause Ca 2ϩ desensitization (see Ref. 24 for review). In addition to vasorelaxant agents acting by the generation of cyclic nucleotides, there exists another force-inhibiting system activated by concentrations of G protein-coupled receptor (GPCR) stimuli greater than the EC 50 value, termed "arterial memory," which acts as a negative feedback mechanism by also causing Ca 2ϩ desensitization (32, 33, 35a). Ca 2ϩ sensitization of contraction can be caused by activation of ROK and PKC, and both systems appear to operate to varying degrees when VSM is stimulated by GPCRs (3) and reviewed by (6, 40, 45, 50) . Because of the complexity inherent in this integrative cell signaling network, the precise mechanism(s) by which relaxant agents and contractile GPCR-induced negative feedback (i.e., arterial memory) control the degree of overall Ca 2ϩ sensitization remains to be determined. The present study was designed to examine and compare Ca 2ϩ desensitization causing relaxation that is induced by activation of PKA, PKG, and arterial memory, and that specifically involves alterations in the ROK signaling pathway. To achieve this end, we examined force, [Ca 2ϩ ] i , MLC phosphorylation, and myosin phosphatase target protein-1 (MYPT1) site-specific phosphorylation produced by K ϩ depolarization (KCl) in rabbit artery. KCl has been used extensively as a smooth muscle contractile stimulus to bypasses GPCR activation and cause force development and maintenance by stimulating only increases in [Ca 2ϩ ] i (see Ref. 10 for review). However, recent studies (20, 41, 42, 48) indicate that KCl also causes Ca 2ϩ sensitization solely by activation of ROK, not by activation of both ROK and PKC like many GPCR stimuli [3, and reviewed by Ratz et al. (37)]. Results from this study will provide information that can be used in the formation of a more comprehensive and integrative model of the regulation of smooth muscle contraction.
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METHODS
Tissue preparation. Tissues were prepared as previously described (31) . Femoral arteries from adult New Zealand White rabbits were cleaned of adhering tissue and stored in cold (0 -4°C) physiological saline solution composed of (in mM) 140 NaCl, 4.7 KCl, 1.2 MgSO 4, 1.6 CaCl 2, 1.2 NaHPO4, 2.0 MOPS (adjusted to pH 7.4), 0.02 Na2 (with EDTA to chelate heavy metals), and 5.6 D-glucose. To produce K ϩ depolarization, KCl (110 mM) was substituted isosmotically for NaCl. High-purity water, 17 M⍀ distilled and deionized, was used throughout. The endothelium of each artery was removed by gently rubbing the intimal surface with a metal rod.
Isometric force. Contractile force (F) was measured as previously described (31) . Tissues were cut into 3-to 4-mm-wide artery rings and each muscle ring was secured in a tissue bath (Radnoti Glass Technology, Monrovia, CA) between stainless steel wires attached to a micrometer and isometric force transducer for, respectively, length adjustments and isometric force measurements (model 52, Harvard Apparatus, S. Natick, MA). Tissues were allowed to equilibrate for 1 h at 37°C in physiological saline solution with aeration. The muscle length for which active force was maximum (Lo) was determined for each tissue using an abbreviated length-tension curve and KCl as the stimulus (7, 35 ]i was measured as previously described (31) . Tissues at Lo in an aerated muscle chamber designed for microscopic imaging (Danish Myo Technology) were placed on the stage of an inverted microscope (Olympus IX71) and loaded for 2.5 h with 7.5 M fura 2-PE3 (AM) and 0.01% (wt/vol) Pluronic F-127 (TefLabs, Austin, TX) to enhance solubility. Fluorescence emission at 510 nm was collected by a photomultiplier tube for excitations at 340 and 380 nm (DeltaRam V, Photon Technology International, Lawrenceville, NJ) and emission intensities were expressed as 340 nm/380 nm ratios using Felix software (Photon Technology International) to measure changes in [Ca 2ϩ ]i. Background fluorescence, determined by incubating tissues in 4 mM MnCl2 plus 30 M ionomycin, was subtracted from all 340 nm and 380 nm signals before calculating the 340 nm/380 nm fluorescence ratios.
MLC phosphorylation. Two-dimensional (isoelectric focusing/ SDS-PAGE) was performed as previously described (31, 48) to measure the degree of MLC phosphorylation. Isoelectric variants of the 20-kDa light chains were detected by colloidal gold stain (Amersham) and quantified after digitization by Scion Image Software.
Western blot analysis. Phosphorylation of MYPT1 was measured by Western blot analysis using phospho-specific antibodies as described previously (34) . Artery rings were quick-frozen in an acetonedry ice slurry, thawed, homogenized in 1% SDS, 10% glycerol, 20 mM dithiothreitol, 25 mM Tris ⅐ HCl (pH 6.8), 5 mM EGTA, 1 mM EDTA, 50 mM NaF, 1 mM sodium orthovanadate, 20 mg/ml leupeptin, 2 mg/ml aprotinin, and 20 mg/ml 4-(amidino-phenyl)-methanesulfonyl fluoride, heated 10 min at 100°C, clarified by centrifugation at 5,000 g for 10 min, and stored at Ϫ70°C. Thawed homogenates were assayed for protein concentration and loaded into gel wells at 10 g for total MYPT1 and 50 g for phospho-MYPT1 assays. Proteins were separated by one-dimensional SDS-PAGE on 12% gels, followed by Western blot analysis onto Immobilon-P membranes (Millipore; Bedford, MA). Phosphorylated MYPT1 was identified using anti-MYPT1-p853 and anti-MYPT1-p696 antibodies (Upstate) and total MYPT1 (BD Transduction Labs) was assessed to quantify loading accuracy. Antibodies were detected using horseradish peroxidase-labeled secondary antibody (Santa Cruz) and enhanced chemiluminescence (ECL) and ECL film (Amersham). Quantification of visualized bands was obtained by digital image analysis (Scion Image software). To compensate for gel-to-gel variability and efficiencies of Western blot analysis, antibody labeling, ECL reaction, and film development, a control basal sample, was included in one lane of each gel, and band intensities from other lanes were reported as the degree of change from control basal.
Tissue permeabilization. Artery rings at Lo were depleted of sarcoplasmic reticular Ca 2ϩ by contracting three times with 10 M phenylephrine (PE) in a Ca 2ϩ -free solution. The tissues were then permeabilized with 40 M ␤-escin at 5°C for 45 min and continued for 60 min at 30°C. The initial treatment with ␤-escin at a low temperature helps the slow penetration and/or binding of ␤-escin to the surface membrane of the smooth muscle cells (18) . ␤-Escin was dissolved in a "relaxing solution" contained 74.1 mM potassium methanesulfonate, 4.0 mM magnesium methanesulphonate, 4 mM Na 2ATP, 4 mM EGTA, 5 mM creatine phosphate, and 30 mM PIPES, neutralized with 1 M KOH to pH 7.1 at 20°C. Ionic strength was kept constant at 0.18 M by adjusting the concentration of potassium methanesulfonate. To activate muscle contraction at Ca 2ϩ -clamped levels of 1 M (pCa ϭ 6) and 10 M (pCa ϭ 5) free Ca 2ϩ , a "contracting solution" was made by including the appropriate volume of a 1 M CaCl 2 stock (Fluka), as determined using WEBMAXC (27) . Calmodulin (1 M) was added to the solutions throughout each experiment to compensate for its loss during permeabilization. To induce relaxation for relaxation velocity measurements, tissues precontracted with pCa ϭ 6 contracting solution were rapidly washed in the relaxing solution (pCa ϭ 9) containing 3 M wortmannin to inhibit MLC kinase activity.
Drugs. 8-bromo-cGMP (8br-cGMP), dibutyryl cAMP (db-cAMP), nifedipine, and phentolamine were from Sigma. Forskolin (FSK), ionomycin, S-nitroso-N-acetylpenicillamine (SNAP) and Y-27632 were from Calbiochem. Fura 2-PE3 (AM) and Pluronic F-127 were from Tef Labs (Austin, TX). Nifedipine and ionomycin were dissolved in ethanol; FSK was dissolved in dimethylsulfoxide (DMSO). Ethanol and DMSO were added at a final concentration no Ͼ0.1%, a concentration that had no effect on KCl-induced contraction.
Statistics. The null hypothesis was examined using Student's t-test (when 2 groups were compared) or with one-way ANOVA. To determine differences between groups following ANOVA, the Student-Neuman-Keuls post hoc test was used. In all cases, the null hypothesis was rejected at P Ͻ 0.05. For each study described, the n value was equal to the number of rabbits from which arteries were taken. [Ca 2ϩ ] i . FSK at 1 M (Fig. 1A) , and 8bc-GMP at 100 M (Fig. 1C) , when added 20 min before and during stimulation with KCl produced a moderate inhibition of KCl-induced tonic (10 min) force (ϳ20 -30%), whereas 10 M FSK caused a strong inhibition of ϳ60% (Fig. 1B) . In this study and all subsequent studies, relaxant agents were added at least 20 min before and during stimulation with KCl (except for those agents shown in Figs. 2 and 7) . KCl-induced peak force, however, was not inhibited even by 10 M FSK (Fig. 1,  A-C) . To assess the ability of FSK and 8b-cGMP to inhibit KCl-induced increases in [Ca 2ϩ ] i , tissues were contracted twice with KCl, a first time in the absence (control, C), and a second time in the presence (ϩrelaxant, R), of FSK or 8b-cGMP (see Fig. 1D for example of protocol). Neither 10 M FSK (Fig. 1E) nor 100 M 8br-cGMP (Fig. 1F) (Fig. 2B ) and force (data not shown) in fura-loaded tissues. Effect of FSK, db-cAMP, 8b-cGMP, and SNAP on KClinduced increases in force and MLC phosphorylation. At 10 M, FSK altered neither basal MLC phosphorylation nor basal force (data not shown), but did produce strong (ϳ60%) reductions in KCl-induced increases in tonic (10 min) MLC phosphorylation and force ( Fig. 3; open triangle) . A lower FSK concentration (1 M) also significantly reduced both KClinduced tonic increases in MLC phosphorylation ( Fig. 3, inset ; F) and force, but by a lesser degree (Fig. 3, solid triangle) . The effect of FSK was most likely due to increases in cAMP levels causing PKA activation because 1 mM db-cAMP, a cellpermeable activator of PKA, likewise reduced KCl-induced tonic increases in MLC phosphorylation ( Fig. 3, inset ; cA) and force (Fig. 3 , inverted triangle). 8b-cGMP (100 M) did not significantly reduce basal MLC phosphorylation or force (data not shown), but did reduce the average KCl-induced steadystate MLC phosphorylation level. This reduction was not significantly different than control despite the finding that the average value was close to that produced by 1 M FSK ( Fig.  3, inset; cG) . When taking the reduction by 8b-cGMP in average basal MLC phosphorylation into account, 8bc-GMP reduced the average value for a KCl-stimulated tonic increase in MLC phosphorylation by only 1% compared with control. Moreover, 100 M 8b-cGMP ϩ 10 M FSK (Fig. 3 , solid octagon) significantly reduced the level of tonic force produced by KCl compared with that produced by 10 M FSK alone (Fig. 3 , solid triangle with center hole), but MLC phosphorylation was not further inhibited. Also, 30 M SNAP appeared to reduce KCl-induced tonic force without reducing MLC phosphorylation (n ϭ 2). In general, activation of PKA produced nearly equivalent reductions in MLC phosphorylation and force, and activation of PKG to a level that inhibited force by ϳ20 -30% appeared to do so, in part, through a MLC phosphorylation-independent mechanism. However, high concentrations of NO invoked by 100 M SNAP that caused strong inhibition of force may additionally cause a reduction in MLC phosphorylation similar to that seen by activators of PKA.
RESULTS

Effect of FSK, 8b-cGMP, and SNAP on KCl-induced increases in force and
Effect of FSK, db-cAMP, 8b-cGMP, and SNAP on the ability of Y-27632 to cause relaxation of a KCl-induced tonic contraction. Y-27632 inhibits ROK, causing relaxation of KClinduced contraction without reducing KCl-induced increases in [Ca 2ϩ ] i (20, 41, 48) . Thus inhibition of ROK and activation of PKA and PKG cause relaxation of KCl-contracted artery exclusively by causing Ca 2ϩ desensitization. Moreover, inhibition of ROK by Y-27632 (20, 41, 48) and activation of PKA by FSK (see Fig. 3 ) both cause reductions in KCl-stimulated tonic increases in MLC phosphorylation, suggesting that these two relaxant agents share a common relaxant mechanism. However, 100 M 8b-cGMP caused relaxation by a mechanism largely independent of a reduction in MLC phosphorylation (see Fig. 3 ). If PKA activation and ROK inhibition share a common relaxant cell signaling pathway, then FSK plus Y-27632 should not induce significantly more relaxation of a KCl-contracted tissue than would Y-27632 alone. Likewise, if PKG activation and ROK inhibition do not share the same relaxant signaling pathway, then 8b-cGMP plus Y-27632 should induce a greater relaxant effect than would either agent alone. To test this hypothesis, tissues were contracted with KCl in the absence (control) and presence of 1 M and 10 M FSK and 100 M 8b-cGMP, and at steady state (ϳ15-20 min), relaxed by addition of 3 M Y-27632 (Fig. 4A) . Y-27632 alone caused ϳ50% relaxation of KCl-contracted artery (Fig. 4B , Con), and caused ϳ60% relaxation of tissues contracted with KCl in the presence of FSK (Fig. 4B ). This small difference in the average values of percent relaxation was not statistically significant. However, Y-27632 produced a nearly complete relaxation (Ͼ80%) of tissues contracted with KCl in the presence of 8b-cGMP ( Fig. 4B ; 8br-cG) that was significantly greater than the 50 -60% relaxation produced by control tissues and by tissues exposed also to FSK. Moreover, relaxation in the presence of the NO donor, SNAP, was comparable to that produced in the presence of 8b-cGMP (30 M SNAP: 76 Ϯ 3%, 100 M SNAP: 81 Ϯ 2%, n ϭ 2), while relaxation in the presence of db-cAMP was comparable to that produced in the presence of FSK (1 mM db-cAMP: 55 Ϯ 1%, n ϭ 2). These data support the hypothesis that PKA and Y-27632 caused Ca 2ϩ desensitization by the same mechanism, namely, inhibition of ROK, whereas PKG can act by a pathway distinct from ROK inhibition.
Effect of 8b-cGMP and FSK on the ability of PE pretreatment to induce Ca
2ϩ desensitization. Arterial memory is the term used for the reversible, postreceptor, postactivation, Ca 2ϩ desensitization of contractions induced by prior stimulation of VSM using moderate-to-high concentrations of a contractile receptor stimulus such as PE (32, 33, 35a, 36) . How PE pretreatment induces arterial memory remains to be determined. However, arterial memory and PKA activation both cause relaxation exclusively by causing Ca 2ϩ desensitization because both cause reductions in KCl-induced increases in tonic force and MLC phosphorylation without causing reductions in KCl-induced increases in [Ca 2ϩ ] i . Activation of PKG, while causing Ca 2ϩ desensitization (reduction in force without a reduction in [Ca 2ϩ ] i ), appears to act, at least in part, downstream from regulation of MLC phosphorylation in KCl-activated rabbit artery. If PKA and PKG act through different mechanisms to cause Ca 2ϩ desensitization, then FSK and 8b-cGMP should affect arterial memory in distinctly different ways. To test this hypothesis, tissues were pretreated for 30 min with 10 M PE alone (Fig. 5A , "5"), and with PE ϩ 100 M 8b-cGMP (Fig. 5A, "3" ) and PE ϩ 3 M FSK (Fig. 5A  "2") . Relaxant agents were added 20 min before the addition of PE to ensure equilibration within the tissues. After the 30-min contraction period, tissues were relaxed for 10 min by washout of PE (relaxant agents were also washed from the tissues), and subsequently contracted with KCl (Fig. 5A) . The degree of downregulation of KCl-induced tonic force is a measure of the degree of arterial memory induced by PE pretreatment. Interestingly, steady-state (30 min) contraction induced by PE (1.14 Ϯ 0.05, n ϭ 7) was inhibited equally well by 8b-cGMP (0.95 Ϯ 0.03, n ϭ 4, P Ͻ 0.05 compared with PE alone) and FSK (0.91 Ϯ 0.06, n ϭ 3, P Ͻ 0.05 compared with PE alone; see Fig. 5A ). Despite equivalent effects on the PE-induced contraction, exposure of tissues to FSK and 8b-cGMP during the PE-induced contraction resulted in very different effects when tissues washed free of PE, FSK, and 8b-cGMP were subsequently contracted with KCl (Fig. 5) . As expected based on previous studies (32, 33, 35a, 36) , PE pretreatment alone caused a strong inhibition of subsequent KCl-induced tonic force ( Fig. 5 ; compare "5" and "1"). By contrast, in the presence of 8b-cGMP, PE pretreatment caused a stronger inhibition of subsequent KCl-induced tonic force (Fig. 5, "3") . The very strong inhibition of tonic force revealed during stimulation with KCl subsequent to pretreatment with PE ϩ 8b-cGMP was not due to a long-lasting effect of 8b-cGMP alone because pretreatment for 50 min with 8b-cGMP in the absence of PE did not cause a significant inhibition of tonic force during a subsequent contraction with KCl (Fig. 5, "4") . Likewise, pretreatment with FSK alone had no effect on the strength of a subsequent KCl-induced contraction (data not shown). Notably, in the presence of FSK, PE pretreatment did not significantly inhibit a subsequent KCl-induced tonic contraction (Fig. 5, "2") . That is, FSK prevented arterial memory. These data provide strong support for the hypothesis that PKA and PKG act to cause Ca 2ϩ desensitization by different mechanisms.
Effect of 8b-cGMP, FSK, and PE-pretreatment on MYPT1 phosphoryation. The degree of Ca 2ϩ sensitivity of smooth muscle contraction is regulated, in part, by the degree of MYPT1 phosphorylation at both Thr 853 and Thr 696 (4, 8, 11, 26, 49) . Because PE pretreatment and activation of PKA can cause Ca 2ϩ desensitization by reducing the degree of MLC phosphorylation, but activation of PKG appears to work by a mechanism downstream from regulation of MLC phosphorylation, we tested the hypothesis that PE pretreatment and FSK, but not 8b-cGMP, can alter the degree of MYPT1 phosphorylation.
FSK (10 M) reduced, 8b-cGMP (100 M) had no effect on, and PE pretreatment increased, the degree of basal MYPT1-p853 (Fig. 6A) , whereas only 8b-cGMP caused an elevation in the level of basal MYPT1-p696 (Fig. 6B) . At 2 min of KCl-induced contraction, MYPT1-p853 was elevated above the basal level in control tissues and in tissues exposed to 8b-cGMP, but not in tissues exposed to FSK or in tissues that had been pretreated with PE (Fig. 6A) . KCl did not cause an increase above the basal level in MYPT1-p696, and FSK, 8b-cGMP and PE pretreatment also exerted no effect on KCl-induced MYPT1-p696 (Fig. 6B) . In summary, the pattern of MYPT1 phosphorylation was different when comparing the effects of FSK, 8b-cGMP, and PE pretreatment. However, it was apparent that both PE pretreatment and FSK, but not 8b-cGMP, prevented the KCl-induced increase of MYPT1-p853 observed at 2 min. These data are consistent with the hypothesis that PE pretreatment and PKA, but not PKG, caused Ca 2ϩ desensitization by allowing MLC phosphatase activation through prevention of KCl-activated, MYPT1-p853-induced MLC phosphatase inhibition.
Effect of 8b-cGMP and FSK on relaxation in permeabilized tissues. The rate of relaxation of permeabilized arterial smooth muscle is limited by the rate of MLC phosphatase activity (21) . Thus the rate of relaxation from a precontracted state induced by exposure of permeabilized tissues to a Ca 2ϩ -free solution containing a MLC kinase inhibitor can be used as an indirect measure of the MLC phosphatase activity in Ca 2ϩ clamped but otherwise intact smooth muscle tissue (14) . Moreover, it is well known that activation of both PKA and PKG can relax Ca 2ϩ -contracted permeabilized smooth muscle (30) . In the present study, we found that 100 M 8b-cGMP and 10 M FSK relaxed permeabilized rabbit artery contracted with pCa 6 by ϳ30% (Fig. 7, B, C, and E) , and compared with control (Fig.  7A ), 8b-cGMP (Fig. 7B) and FSK (Fig. 7C) increased the rate of relaxation produced when tissues precontracted with pCa 6 were exposed to relaxing solution (Fig. 7, D and F) . These data suggest that both FSK and 8b-cGMP caused relaxation of Ca 2ϩ activated permeabilized muscle by enhancing MLC phosphatase activity. Together, the results from this study suggest that permeabilized and intact muscle display differences in responsiveness to FSK and 8b-cGMP.
DISCUSSION
Extensive research over the past several decades have revealed that vasorelaxant agents increase the activities of PKA and PKG, which act on multiple substrates to cause reductions both in [Ca 2ϩ ] i and Ca 2ϩ sensitivity (see Refs. 15, 23, and 29 for reviews). The present study provides cell physiological evidence that PKA and PKG can act by separate mechanisms in intact tissues to cause Ca 2ϩ desensitization of VSM (Fig. 8) . These separate mechanisms were revealed by examining relaxant effects in tissues stimulated to contract using KCl, a stimulus that bypasses GPCR activation. KCl causes contraction by elevating Ca 2ϩ entry and by activating ROK-induced Ca 2ϩ sensitization (see Ref. 37 for review), whereas GPCR activation additionally generates PKC␣/PKC␦-induced Ca 2ϩ sensitization involving CPI-17 (3). During KCl-induced contraction of rabbit artery, both FSK and 8b-cGMP caused relaxation solely by causing Ca 2ϩ desensitization, because neither FSK nor 8b-cGMP caused reductions in stimulated [Ca 2ϩ ] i , but both agents caused reductions in tonic force. Both FSK and 8b-cGMP appeared to elevate MLCP activity in permeabilized artery because both agents increased the rate of relaxation. Moreover, activation of PKA by FSK and dbcAMP, and strong activation of PKG by 100 M SNAP, caused concomitant reductions in KCl-induced tonic increases in MLC phosphorylation and force in intact tissues. However, weaker activation of PKG by 30 M SNAP or 100 M 8b-cGMP, and especially by 100 M 8b-cGMP in the presence of 10 M FSK, caused ϳ20 -30% inhibition of KCl-induced tonic force, whereas inducing either no reduction, or less of a reduction, in MLC phosphorylation. Together, these data support studies indicating that both FSK and 8b-cGMP can cause relaxation by acting at the level of MLCP regulation (2, 24, 43, 53, 54) but introduce the idea that in intact artery stimulated with KCl, whereas FSK activates this mechanism even at 1 M, weak activation of PKG by 8b-cGMP may cause relaxation also by acting downstream from MLCP regulation to dissociate MLC phosphorylation from tonic force. These results provide strong support for the hypothesis that, despite the potential for extensive cross-talk (see Refs. 16 and 28 for review). PKA and PKG do not necessarily converge on identical signaling pathways to cause relaxation. Although the precise mechanisms causing dissociation of MLC phosphorylation from contraction remain to be determined, both thinfilament regulatory proteins and heat shock protein-20 may play a role (22, 39, 52) .
Another important finding was that the mechanism causing Ca 2ϩ desensitization in tissues pretreated with a contractile GPCR agonist (in this case, the ␣-adrenergic receptor agonist PE) appeared to be the same mechanism used by the relaxant, FSK, and not 8b-cGMP (Fig. 8) . A surprising but enlightening consequence of this convergence of Ca 2ϩ -desensitizing signals was that the delayed Ca 2ϩ desensitization invoked in tissues by pretreatment with PE was actually reversed by simultaneous exposure of tissues to PE and the activator of PKA, FSK (Fig.  8) . That is, PE pretreatment in the presence of FSK did not lead to Ca 2ϩ desensitization during a subsequent KCl-induced contraction, as it does in the absence of FSK (see Fig. 5 ). Thus perhaps the most novel aspect of the present study is the revelation that VSM retains a "memory" of prior exposure to GPCR agonists and relaxant agents such that the degree of Ca 2ϩ sensitivity produced subsequently can yield nearly the full range of contractile responses from very weak to very strong (see Fig. 5A ). That is, the degree of Ca 2ϩ sensitivity produced at any given instance reflects, for some time, the relative activity levels of prior stimulation with GPCR agonists and relaxant agents activating PKA and PKG. One implication is that, not only do the signaling systems involved in regulating Ca 2ϩ sensitivity exist in a complex spatiotemporal organization (see Ref. 5 for review), but the temporal duration of Fig. 8 . Working model depicting how 8b-cGMP, FSK, and PE pretreatment inhibited KCl-induced tonic contraction. Solid arrows indicate activation, solid lines ending in a large dot indicates inhibition. Although PE pretreatment and PKA activation by FSK individually caused relaxation of KCl-induced tonic force by inhibiting the ability of ROK to cause Ca 2ϩ desensitization, PE pretreatment in the presence of FSK did not, permitting strong force maintenance (see Fig. 5 ). Data from this study support the hypothesis that activation of PKG sufficient to cause ϳ30% reduction in KCl-induced force may act downstream from MLCP regulation. However, PKG can also, like PKA, cause relaxation by activation of MLCP, but likely by a mechanism different than that activated by PKA. EM and EK are, respectively, membrane potential and K ϩ equilibrium potential. PM, plasma membrane. influence on contraction is not restricted solely to the duration of exposure to the stimuli activating the mechanisms. Rather, the influence of GPCR agonists and of activators of PKA and PKG can last for some time after complete cessation of the stimulation period, when tissues are otherwise in their basal state. The consequence is an ability of VSM to produce highly variable degrees of Ca 2ϩ sensitivity, and therefore, force (see Fig. 5A for example) . Additional studies are required to identify how Ca 2ϩ desensitizing signaling systems induced by PKA and PE pretreatment interact spatially and temporally at the subcellular level.
PKA and PKG potentially can cause reductions in ROKinduced Ca 2ϩ sensitization (2, 13, 24, 43, 53, 54) . Moreover, the present study supports this contention because FSK and 8b-cGMP did appear to increase MLCP activity in permeabilized artery. Thus, it was somewhat surprising that in KClstimulated intact tissues, PKG activation was found to cause relaxation, in part, by a mechanism that appeared to be independent of reductions in MLC phosphorylation levels, at least when PKG was stimulated with 100 M 8b-cGMP or 30 M SNAP, concentrations that induced inhibition of tonic force by ϳ30%. However, nitrovasodilators uncouple force from MLC phosphorylation in intact swine carotid artery stimulated with histamine (19) . Moreover, in support of these data, we also found that 8b-cGMP did not reduce the increase in MYPT1-p853 produced by KCl, whereas both FSK and PE pretreatment did. Although PKG (1) may cause Ca 2ϩ desensitization by inhibiting CPI-17 phosphorylation, KCl does not elevate CPI-17 phosphorylation in rabbit femoral artery (11) . Interestingly, 8b-cGMP alone elevated the basal level of MYPT1-p696, but this increase was not evident during KCl stimulation. Because phosphorylation at both MYPT1-p853 and MYPT1-p696 have been linked to MLCP inhibition (4, 8, 11, 26, 49) , the significance of this increased basal MYPT1-p696 phosphorylation was unclear. One possible explanation is that the phospho-specific antibody used could not clearly discriminate between MYPT1-p696 and MYPT1-p695, and that 8b-cGMP actually caused an increase in MYPT1-p695, not MYPT1-p696. PKG does not directly inhibit MLCP activity despite phosphorylation of MYPT1, but rather, causes reductions in MLCP-plasma membrane binding (25) . A recent study (53) has revealed that phosphorylation by PKA and PKG of sites adjacent to those involved in regulation of MLCP activity has no direct effect on MLCP activity, but inhibits the ability of ROK to phosphorylate the MYPT1 regulatory sites. Moreover, PKG directly binds MYPT1, and uncoupling of this interaction decreases the ability of PKG to phosphorylate MYPT1 (46) . In summary, 8b-cGMP caused an increase in MYPT1-p696 (or possibly MYPT1-p695) before muscle stimulation with KCl, but this phosphorylation, as well as MYPT1-p853, was not elevated above the basal level during KCl-induced contraction in the presence of 8b-cGMP. Together, this information supports a speculative model that PKG and MYPT1 were associated before stimulation with KCl, but not during the KClinduced contraction, and that during a KCl-induced contraction, PKA (but not PKG) can access MYPT1 to prevent MYPT1-p853, permitting MLCP activation. In any event, it is clear that a complete understanding of in situ regulation of MLCP activity will likely require a great deal of spatiotemporal information about phosphorylation status and location(s) of both catalytic and regulatory subunits and their binding partners.
In conclusion, a growing body of literature implicates altered Ca 2ϩ sensitization and desensitization pathways in many disorders involving dysregulation of vascular smooth muscle contraction, including hypertension (47), vasospasm (17, 44) , and hemorrhagic shock (55) . The degree of Ca 2ϩ sensitivity of contraction is not only dependent on the integration of signals from various contractile and relaxant stimuli, but also, as revealed by the present study, on the history of VSM stimulation. To fully understand the implications of dysregulation of Ca 2ϩ sensitivity and its relation to certain vascular disorders, what will be required is a more complete understanding not only of direct, or immediate, stimulus-response coupling mechanisms, but also of mechanisms permitting VSM to retain information about prior stimulation, and of how such information is integrated into the spatiotemporal signaling network controlling Ca 2ϩ sensitivity.
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